[Amgen's] going to use every means at its disposal to protect its intellectual property rights and keep Roche off the market. We'll have to see how the courts interpret it, of course. This is a very real risk to the stock.
I don't think they have an issue in the marketplace. Operationally, they're hitting their stride ... but this is a stock that has to trade on more near-term earnings.
I think you're going to see a bit of a struggle between patients and physicians going forward, which I think can blunt the near-term uptake of the drug.
It doesn't matter what the real outcome is for a long time. In the meantime we're going to see some volatility just on the headlines.
Its hard to really spin these results positively in terms of the revenue mess.
Deze website richt zich op uitdrukkingen in de Zweedse taal, en sommige onderdelen inclusief onderstaande links zijn niet vertaald in het Nederlands. Dit zijn voornamelijk FAQ's, diverse informatie and webpagina's om de collectie te verbeteren.
Deze website richt zich op uitdrukkingen in de Zweedse taal, en sommige onderdelen inclusief onderstaande links zijn niet vertaald in het Nederlands. Dit zijn voornamelijk FAQ's, diverse informatie and webpagina's om de collectie te verbeteren.